Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

Helen Kakkassery, Esme Carpenter, Piers E.M. Patten, Sheeba Irshad*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)

Abstract

Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and nonreplicating viral vector vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca). Impaired or delayed humoral and diminished T-cell responses are evident in patients with cancer, especially in patients with haematological cancers or those under active chemotherapy. Herein we review the current data on vaccine immunogenicity in cancer patients, including recommendations for current practice and future research.

Original languageEnglish
Pages (from-to)1082-1099
Number of pages18
JournalTRENDS IN MOLECULAR MEDICINE
Volume28
Issue number12
DOIs
Publication statusPublished - Dec 2022

Keywords

  • cancer
  • COVID-19
  • haematological cancers
  • SARS-CoV-2
  • seroconversion
  • vaccine immunogenicity

Fingerprint

Dive into the research topics of 'Immunogenicity of SARS-CoV-2 vaccines in patients with cancer'. Together they form a unique fingerprint.

Cite this